Status:
COMPLETED
Engineering Gut Microbiome to Target Breast Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to find out if using probiotics will help the body's immune system react to breast cancer. New studies showed that diverse species of bacteria inside the bowel might help ...
Eligibility Criteria
Inclusion
- Post-menopausal females ≥ 18 years of age
- Histologically confirmed adenocarcinoma of the breast ≥1.0 cm operable stage I-III
- Must have adequate organ function,
- Not receive systemic neoadjuvant therapy
- Be willing to provide tissue, blood, and stool samples for research study.
- Must not have taken any probiotics in the past 60 days prior to enrollment.
Exclusion
- Patients with autoimmune disease, immune deficiency such as HIV, irritable bowel, known diverticulosis, and other serious GI conditions at treating physician's discretion will be excluded.
Key Trial Info
Start Date :
October 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 19 2020
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03358511
Start Date
October 11 2017
End Date
May 19 2020
Last Update
May 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224